Mumbai-based pharmaceutical major Lupin will acquire Netherlands-based VISUfarma B.V. for an enterprise value of EUR 190 million (about Rs 2,000 crore) through its wholly owned subsidiary Nanomi B.V., ...
A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback to its efforts to defend the blockbuster therapy from generic ...
The inspection was held between September 8 and 16. Lupin did not disclose the details of the observations but said it would respond within the required timeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback